

Postdoctoral position (M/F)

General Information

Duration	24-month fixed-term contract Expected start date: September–December 2026 Renewable : ☒ OUI ☐ NON
Working time	Full-time
Salary	from €2,939 gross per month, depending on experience

Job description

About the team	The “Cancer Cell Plasticity in Melanoma” team, co-led by Julie Caramel (INSERM Research Director, DR2) and Stéphane Dalle (Professor/Hospital Practitioner, Head of the Oncodermatology Department at Lyon Sud Hospital), develops fundamental and translational research projects aimed at determining the mechanisms underlying initiation, tumor progression, and treatment resistance in cutaneous melanoma, with a particular focus on non-genetic mechanisms of tumor plasticity.
-----------------------	---

Main missions and activities	The successful candidate will be responsible for characterizing the different states of tumor cells, their interactions with immune and stromal cells, and their role in malignant transformation and early progression in patients with cutaneous melanoma. Based on the analysis of a unique spatial transcriptomics dataset from matched melanoma and nevi samples, the candidate will develop in vitro and in vivo (mouse models) approaches to target tumor–microenvironment interactions in order to intercept tumor development.
-------------------------------------	--

Required skills	• Expertise in immuno-oncology • Cell culture • Molecular biology • Flow cytometry • Animal experimentation
------------------------	---

Abilities	• Autonomy and ability to successfully carry out a research project • Strong planning, organizational, and interpersonal skills • Excellent communication and writing skills • Proficiency in English
------------------	--

**Degree level and
training(s)**

- PhD

Modalités de candidature

Deadline

August 31, 2026

Contact

Please send a CV, cover letter, and contact details of 2–3 references to:
stephane.dalle@chu-lyon.fr
Shortlisted candidates will be contacted for an interview with the team leaders.

Recent Publications

- 2026**
- Pham F, et al. Spatial tumour-immune ecosystems shape the efficacy of anti-PD1 immunotherapy in primary cutaneous melanoma. *J Immunother Cancer*, 2026.
 - Tselikas L, et al. Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1. *Nature*. 2026.
- 2025**
- Durand S, et al. The epigenetic regulator TRIM24 controls melanoma cell dedifferentiation and resistance to treatment in melanoma. *BioRxiv* 2025.
 - Gobbin E, et al. cDC1 spatial organization with CD8 T cell is critical for the response to immune checkpoint inhibitors in melanoma patients. *Cancer Immunology Research*. 2025.
- 2024**
- Durand S, et al. ZEB1 controls a lineage-specific transcriptional program essential for melanoma cell state transitions. *Oncogene*, 2024.
- 2022**
- Plaschka M, et al. ZEB1 transcription factor promotes immune escape in melanoma. *J Immunother Cancer*, 2022.
- 2016**
- Richard G, et al. ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors. *EMBO Mol Med*. 2016. 8: 1143-1161.
- 2013**
- Caramel J., et al. A Switch in the Expression of Embryonic EMT-Inducers Drives the Development of Malignant Melanoma. *Cancer Cell* 2013, 24, 466-480.

Host Institution

A propos du CRCL

The Cancer Research Center of Lyon is a research unit labeled by Inserm, CNRS, Université Claude Bernard Lyon 1 and Centre Léon Bérard. Composed of 23 teams and 13 technological platforms, its activity is dedicated to the study of cancer biology.

Director

Dr Patrick MEHLEN

Team

"Cancer Cell Plasticity in Melanoma" (Julie Caramel and Stéphane Dalle)

Address

CRCL - Centre Léon Bérard - 28 rue Laennec - 69373 Lyon cedex 08

To find out more

www.crcl.fr
<https://www.crcl.fr/en/research-teams/cancer-cell-plasticity-in-melanoma/>